Unity Biotechnology (UBX) Stock
Healthcare sector company. Here's the price, business snapshot, and what's worth knowing about Unity Biotechnology in October 2026.
UNITY Biotechnology, Inc. is a biotechnology company engaged in researching and developing therapeutics to slow, halt or reverse diseases of aging. The Company is focused on creating medicines to selectively eliminate or modulate senescent cells and thereby provide transformative benefit in age-related ophthalmologic and neurologic diseases. It is targeting specific biological mechanisms implicated in diseases of aging. Its core therapeutic approach targets cellular senescence, and it is advancing senolytic programs primarily in ophthalmologic disorders. It has other programs based on other biologies of aging to include an agonistic antibody to the Tie2 receptor and a Tie2/VEGF bispecific to treat vascular eye disease. UBX1325 is its advanced drug candidate for age-related diseases of the eye, including diabetic macular edema. UBX1325 is a potent small molecule inhibitor of BCL-xL. UBX2089, an a-Klotho hormone drug candidate, is being researched for multiple neurology indications.
Unity Biotechnology (UBX) Stock Forecast
Analyst price target, next 12 months
$6.00
+518.6% vs today's $0.97
Price range over the last 12 months
In the middle of its 12-month range
Analysts covering Unity Biotechnology have a consensus 12-month target of $6.00, above the current price of $0.97.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 11 Apr 2025.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts suggest buying Unity's stock as its target price is significantly higher than its current price.
Financial Health
Unity Biotechnology is generating moderate cash flow and has a relatively low book value per share.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
